GYN/ONC Active Protocols

Tumor Site: CERVIX

GOG 227G
A Phase II Evaluation of Brivanib in the Treatment of Persistent or Recurrent Carcinoma of the Cervix.

GOG 237
Comparative Analysis of CA-IX, p16, Proliferative Markers and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (ACG)

GOG 240
A Randomized Phase III Trial of Cisplatin Plus Paclitaxel with and without NCI-Supplied Bevacizumab versus the Non-Platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent Carcinoma of the Cervix.

GOG 247
Patient, Physician and Nurse Factors Associated with Entry Onto Clinical Trials and completion of Treatment for Women with Primary or Recurrent Invasive Carcinoma of the Uterine Corpus or Uterine Cervix, All Stages 

 

 

Tumor Site: Endometrial

CA163196 BMS
A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who Have Previously Been Treated with Chemotherapy

GOG 0086P
A 3 Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab,
Paclitaxel/Carboplatin/Temsirolimus and Ixabepilone/Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage II or IVA, Stage IVB, or Recurrent Endometrial Cancer

GOG 224
A Randomized Phase II Evaluation of Continuous Progestin Therapy VS Sequential Progestin Therapy I, the Treatment of Endometrial IntraEpithelial Neoplasia (EIN) From A Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients that desire Uterine Preservation

GOG 229H
A Phase II Evaluation of AZD6244 in the Treatment of Recurrent or Persistent Endometrial Carcinoma

GOG 229L
A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium

 

Tumor Site: OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL

MORAb-003-004-Morphotek, Inc.
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO ASSESS THE EFFICACY AND SAFETY OF WEEKLY FARLETUZUMAB IN COMBINATION WITH CARBOPLATIN AND TAXANE IN SUBJECTS WITH PLATINUM-SENSITIVE OVARIAN CANCER IN FIRST RELAPSE 

Lilly Protocol I1Y-MC-JFBF
A Phase 2 Indication Identification Study of LY2523355 in Patients with Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers and Squamous Cell Carcinoma of the Head and Neck

GOG 186G
A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus bevacizumab VS. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

GOG 186I
A Randomized Phase II Evaluation of Single-Agent Bevacizumab and Combination Bevacizumab with Fosbretabulin Tromethamine in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

GOG 187
Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy

GOG 212
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103), Versus NO TX Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Ca Who achieve a Complete Clinical Response to Primary Platinum /Taxane Chemotherapy.


GOG 213
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or In Combination with Bevacizumab followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer.

GOG 235
A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy

GOG 241
A CCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- Bevacizumab Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC)

GOG 254
A Phase II Evaluation of SU11248 (Sunitinib Malate) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma

GOG 260
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer

GOG 262
A Randomized Phase III Trial of Every-3-Weeks Paclitaxel versus Dose Dense Weekly Paclitaxel in Combination with Carboplatin with or without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer

GOG 264
A Randomized Phase II Trial of Paclitaxel and Carboplatin VS Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary

GOG 267
Quality of Life and Care Needs in Patients with Persistent or Recurrent Platinum-Resistant Ovarian, Fallopian Tube and Peritoneal Cancer

GOG 268
A Phase II Evaluation of Temsirolimus in combination with Carboplatin and Paclitaxel Followed by Temsirolimus Consolidation as First-Line Therapy I the treatment of Stage III-IV Clear Cell Carcinoma of the Ovary

GOG 273
Chemotherapy Toxicity in Eldery Women with Ovarian, Primary Peritoneal or Fallopian Tube Cancer
 


Tumor Site: TROPHOBLASTIC NEOPLASIA

GOG 242
A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-Metastatic Gestational Trophoblastic Neoplasia

 

 

 

Tumor Site: UTERUS

 GOG 247
Patient, Physician and Nurse Factors Associated with Entry Into Clinical Trials and completion of Treatment for Women with Primary or Recurrent Invasive Carcinoma of the Uterine Corpus or Uterine Cervix, All Stages

Carcinosarcoma

GOG 130F
A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

GOG 230D
A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus

GOG 261
A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus

Leiomyosarcoma

GOG 131H
A Phase II Evaluation of Ixabepilone in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus

GOG 250
A Randomized Phase III Evaluation of Docetaxel and Gemcitabine Plus G-CSF with Bevacizumab Versus Docetaxel and Gemcitabine Plus G-CSF with Placebo in the TX of Recurrent or Advanced Leiomyosarcoma of the Uterus